Sleep apnea in fragile X premutation carriers with and without FXTAS
- PMID: 21932336
- PMCID: PMC4109408
- DOI: 10.1002/ajmg.b.31237
Sleep apnea in fragile X premutation carriers with and without FXTAS
Abstract
This report seeks to establish the prevalence of sleep apnea in patients with the fragile X mental retardation 1 (FMR1) premutation with and without fragile X-associated tremor/ataxia syndrome (FXTAS) and to determine any correlation between CGG repeat and FMR1 mRNA levels with sleep apnea prevalence. Demographic and medical data from 430 (229 males, 201 females) participants were used in this analysis. Participants included premutation carriers with (n = 118) and without FXTAS (n = 174) as well as controls without the premutation (n = 123). Logistic regression models were employed to estimate the odds ratio of sleep apnea relative to controls, adjusted for age and gender, and also to examine potential association with CGG size and FMR1 mRNA expression level. The observed proportion of sleep apnea in premutation carriers with and without FXTAS and controls are 31.4% (37/118), 8.6% (15/174), and 13.8% (17/123), respectively. The adjusted odds of sleep apnea for premutation carriers with FXTAS is about 3.4 times that compared to controls (odds ratio, OR = 3.4, 95% confidence interval (CI) 1.8-7.4; P = 0.001), and similarly relative to premutation carriers without FXTAS (OR = 2.9, 95% CI 1.2-6.9; P = 0.014). The risk of sleep apnea was not different between controls and premutation carriers without FXTAS. The presence of sleep apnea is not associated with CGG repeat numbers nor FMR1 mRNA expression level among premutation carriers. Our data supports a higher prevalence and risk of sleep apnea in patients with FXTAS. We recommend that all patients diagnosed with FXTAS be screened for sleep apnea given the negative and perhaps accelerative impact sleep apnea may have on their FXTAS progression.
Copyright © 2011 Wiley Periodicals, Inc.
References
-
- Ancoli-Israel S, Kripke DE. Prevalent sleep problems in the aged. Biofeedback Self Regul. 1991;16(4):349–359. - PubMed
-
- Arocena DG, Iwahashi CK, Won N, Beilina A, Ludwig AL, Tassone F, Schwartz PH, Hagerman PJ. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet. 2005;14(23):3661–3671. - PubMed
-
- Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman RJ. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67(1):87–94. - PubMed
-
- Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Mov Disord. 2007;22(14):2018–2030. - PubMed
-
- Berry-Kravis E, Goetz CG, Leehey MA, Hagerman RJ, Zhang L, Li L, Nguyen D, Hall DA, Tartaglia N, Cogswell J, Tassone F, Hagerman PJ. Neuropathic features in fragile X premutation carriers. Am J Med Genet A. 2007;143(1):19–26. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MH077554/MH/NIMH NIH HHS/United States
- K23 MH077554/MH/NIMH NIH HHS/United States
- R01 MH078041/MH/NIMH NIH HHS/United States
- UL1 DE019583/DE/NIDCR NIH HHS/United States
- HD02274/HD/NICHD NIH HHS/United States
- AG032119/AG/NIA NIH HHS/United States
- RL1 AG032119/AG/NIA NIH HHS/United States
- HD036071/HD/NICHD NIH HHS/United States
- R01 HD036071/HD/NICHD NIH HHS/United States
- AG032115/AG/NIA NIH HHS/United States
- P30 HD002274/HD/NICHD NIH HHS/United States
- DA024854/DA/NIDA NIH HHS/United States
- TL1 DA024854/DA/NIDA NIH HHS/United States
- UL1 RR024146/RR/NCRR NIH HHS/United States
- RL1 AG032115/AG/NIA NIH HHS/United States
- DE019583/DE/NIDCR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
